Kajian klinikal Glioma di Georgia
7 kajian untuk Glioma sedang mencari peserta di lokasi di Georgia.
Bandar di Georgia
Teks kajian rasmi (Bahasa Inggeris)
A Study of the Drug Selinexor With Radiation Therapy in Patients With Newly-Diagnosed Diffuse Intrinsic Pontine (DIPG) Glioma and High-Grade Glioma (HGG)
- Children's Healthcare of Atlanta - Arthur M Blank Hospital, Atlanta
Mengambil pesertaFasa 1/2
12 Months – 21 Years · Semua jantina · Dikemas kini 1 Okt 2026 · NCT05099003Study of Silevertinib With Temozolomide for the Treatment of Newly Diagnosed GBM With Unmethylated MGMT and EGFRvIII
- Piedmont Oncology Research, Atlanta
Mengambil pesertaFasa 2
Umur 18 ke atas · Semua jantina · Dikemas kini 28 Sep 2026 · NCT07326566A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations
- Children's Healthcare of Atlanta - Egleston Hospital, Atlanta
Mengambil pesertaFasa 1/2
Sehingga umur 25 · Semua jantina · Dikemas kini 25 Sep 2026 · NCT04094610ACT001 for the Treatment of Diffuse Intrinsic Pontine Gliomas and H3K27-altered High Grade Gliomas
- Emory University/Children's Healthcare of Atlanta, Atlanta
Mengambil pesertaFasa 2
12 Months – 39 Years · Semua jantina · Dikemas kini 21 Sep 2026 · NCT06838676SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance)
- Emory University, Atlanta
Mengambil pesertaFasa 3
Umur 18 ke atas · Semua jantina · Dikemas kini 28 Ogo 2026 · NCT05303519Atovaquone Combined With Radiation in Children With Malignant Brain Tumors
- Arthur M Blank Hospital, Atlanta
- Children's Healthcare of Atlanta: Scottish Rite, Atlanta
Mengambil pesertaFasa 1
Umur 2 hingga 25 · Semua jantina · Dikemas kini 3 Ogo 2026 · NCT06624371Tumor Treating Fields for the Treatment of Brainstem Gliomas
- Emory Proton Therapy Center, Atlanta
- Emory University/Winship Cancer Institute, Atlanta
- Emory Saint Joseph's Hospital, Atlanta
Mengambil peserta
Umur 18 ke atas · Semua jantina · Dikemas kini 26 Sep 2025 · NCT05310448Daripada ClinicalTrials.gov, data diperoleh pada 5 Okt 2026. Setiap kajian menetapkan kriteria kelayakannya sendiri; pasukan kajian menentukan siapa yang layak menyertai.